Skip to main content
Betta Pharmaceuticals Co.,Ltd logo

Betta Pharmaceuticals Co.,Ltd — Investor Relations & Filings

Ticker · 300558 ISIN · CNE100002DD9 LEI · 8368009YF4Y6NC7HVB09 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,656 across all filing types
Latest filing 2018-12-20 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 300558

About Betta Pharmaceuticals Co.,Ltd

https://www.bettapharma.com

Betta Pharmaceuticals Co.,Ltd. focuses on the research, development, and commercialization of innovative oncology medications. The organization specializes in targeted therapies, particularly for the treatment of lung cancer and other solid tumors. Its portfolio includes Icotinib, a small-molecule EGFR tyrosine kinase inhibitor, and Ensartinib, an ALK inhibitor designed for non-small cell lung cancer. The company operates a comprehensive R&D infrastructure dedicated to molecular biology, medicinal chemistry, and clinical development. By prioritizing precision medicine, the firm aims to deliver high-quality therapeutic solutions that address complex oncological challenges. Its pipeline encompasses a diverse range of candidates, including small molecules and biologics, aimed at improving patient outcomes through advanced scientific innovation.

Recent filings

Filing Released Lang Actions
第二届董事会第二十九次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at a board of directors meeting, including details about the meeting's convening, attendance, and voting results on stock option incentive plans. It does not contain financial statements or detailed financial performance data. It is not a full annual or interim report, nor an earnings release. It is not a proxy solicitation or AGM materials but a board meeting resolution announcement. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board or senior management. The document length is short (1690 characters), and it is a direct announcement, not a report publication notice or certification. Therefore, the correct classification is MANG with high confidence.
2018-12-20 Chinese
独立董事关于第二届董事会第二十九次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent director's opinion regarding adjustments and the initial grant of stock options under the company's 2018 (second phase) stock option incentive plan. It discusses compliance with relevant laws and regulations, adjustments to the number of options and recipients, and confirms the legality and appropriateness of the grant. The document is not a full financial report, earnings release, or regulatory filing but rather a formal opinion related to management decisions on stock option incentives. This fits best under Board/Management Information (MANG) as it relates to board-level decisions and management matters concerning stock option plans.
2018-12-20 Chinese
关于2018年（第二期）股票期权激励计划内幕信息知情人及激励对象买卖公司股票情况的自查报告
Regulatory Filings Classification · 95% confidence The document is a self-inspection report regarding the trading activities of insiders and incentive plan participants related to a 2018 stock option incentive plan of the company 贝达药业股份有限公司. It details the investigation scope, procedures, and findings about insider trading activities within a specified period. The document includes lists of individuals and their stock transactions, emphasizing compliance with insider trading regulations and disclosure requirements. It is not a financial report, earnings release, or management discussion, nor is it an announcement of voting results or a capital change. It is a regulatory disclosure related to insider trading compliance and stock option incentive plan insider information. Such documents typically fall under Regulatory Filings (RNS) as they do not fit into other specific categories like Director's Dealing (DIRS) because it covers a broader insider trading self-inspection report rather than individual insider trades only. The document length is about 5032 characters, which is sufficient for a detailed regulatory filing rather than a brief announcement. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2018-12-11 Chinese
2018年第二次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 2018 second extraordinary general meeting of shareholders of Betta Pharmaceuticals Co., Ltd. It includes voting results on multiple proposals related to a stock option incentive plan, details on meeting attendance, voting methods, and legal opinions confirming the validity of the meeting and resolutions. The content is focused on the official results of shareholder votes at a general meeting, including percentages of votes for, against, and abstentions for each agenda item. There is no indication that this is a full annual or interim report, audit report, or other financial report. The document is not a proxy solicitation or investor presentation but specifically reports the voting results of a shareholders' meeting. Therefore, the appropriate classification is Declaration of Voting Results & Voting Rights Announcements (DVA). The document length (6507 characters) and detailed voting data support this classification with high confidence.
2018-12-11 Chinese
2018年第二次临时股东大会的法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the convening, procedures, attendance, and voting results of a company's 2018 second extraordinary general meeting (临时股东大会). It details the legal compliance of the meeting's call, attendance qualifications, agenda items, voting procedures, and results. The document does not contain financial statements or financial performance data, nor is it a report of financial results or management discussion. It is not a notice of voting results but a legal opinion on the validity of the meeting and its procedures. The document is lengthy (8888 characters) and is a formal legal opinion related to a shareholders' meeting. This type of document does not fit into categories like Annual Report, Earnings Release, or Management Reports. It is a legal opinion letter on the shareholders meeting, which is a type of Regulatory Filing (RNS) as it does not fit other categories and is a compliance/legal document related to corporate governance and shareholder meetings.
2018-12-11 Chinese
关于BPI-17509药品临床试验申请获得受理的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the acceptance of a clinical trial application by the National Medical Products Administration (国家药品监督管理局) for a new drug (BPI-17509). It details the acceptance notice numbers, the nature of the drug, and the implications for the company. The document is short (1519 characters) and is an announcement of regulatory acceptance rather than a financial report or detailed management discussion. It does not contain financial data, earnings, or management changes. It is not a report publication announcement since it is not about publishing a report but about regulatory acceptance of a clinical trial application. This fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other categories.
2018-12-06 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.